The largest database of trusted experimental protocols

Vigadexa

Manufactured by Alcon
Sourced in United States

Vigadexa is a laboratory equipment product manufactured by Alcon. It is designed for use in research and scientific applications. The core function of Vigadexa is to provide controlled and precise environmental conditions for conducting experiments and analyses.

Automatically generated - may contain errors

2 protocols using vigadexa

1

Postoperative Topical Treatment and Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
In the immediate postoperative period, topical treatment was initiated with a combination of moxifloxacin and dexamethasone (Vigadexa, Alcon) four times a day for 1 week, and lubricant eye drops containing sodium hyaluronate and carboxymethylcellulose (Optive, Allergan) were provided by Oftalmax. The patients were examined by medical researchers who did not participate in the randomization at day 1, week 1, month 1, 3 months and 1 year after the procedure.
During the first three postoperative follow-up visits, possible complications and ocular surface integrity were assessed by anterior segment biomicroscopy, uncorrected distance visual acuity (UDVA), and fundoscopy. The last two visits included the evaluation of the patients’ visual acuity with cycloplegic refraction, retinal mapping, applanation tonometry, and total anterior segment analysis including RMS and HOAs performed by dual Scheimpflug-based corneal system tomography.
+ Open protocol
+ Expand
2

Preoperative Antibiotic and Steroid Solutions for Cataract Surgery

Check if the same lab product or an alternative is used in the 5 most similar protocols
This prospective clinical study was conducted from January 2012 to February 2013 at the Federal University of São Paulo and Hospital de Olhos Paulista according to the tenets of the Declaration of Helsinki. Institutional review board/ethics committee approval was obtained, and each patient provided written informed consent before enrolment in the study.
Patients scheduled for routine phacoemulsification and IOL implantation were enrolled in this study. Exclusion criteria were patients with ocular surface diseases and those using topical and systemic steroids and antibiotics.
Prior to surgery for cataract, they received one of the following commercially available solutions: Group 1: moxifloxacin 0.5% (Vigamox; Alcon, Fort Worth, TX, USA); Group 2: moxifloxacin 0.5% combined with dexamethasone (Viga dexa; Alcon); Group 3: gatifloxacin (Zymar; Allergan, Dublin, Ireland); and Group 4 gatifloxacin combined with prednisolone (Zypred; Aller gan). Table 1 shows the pharmacological features of the solutions.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!